Active and passive immunotherapy for neurodegenerative disorders

Annual Review of Neuroscience

Volumn 31, Issue , 2008, Pages 175-193

  Brody, David L ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Monoclonal antibody; Vaccination

Indexed keywords

ABB 001; ACC 001; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AN 1972; BAPINEUZUMAB; CAD 106; IMMUNOGLOBULIN; IMMUNOLOGIC AGENT; LY 2062430; PF 4360365; PLACEBO; PRION PROTEIN ANTIBODY; QS 21; R 1450; V 950;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN FUNCTION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFUSION; CONVULSION; DEGENERATIVE DISEASE; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HOSTILITY; HUMAN; MENINGOENCEPHALITIS; NERVE DEGENERATION; NONHUMAN; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; TRANSGENIC MOUSE; VACCINATION;

AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; HUMANS; IMMUNITY; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; VACCINATION;

EID: 47949132196     PISSN: 0147006X     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.neuro.31.060407.125529     Document Type: Review

References (88)

1. Angelov DN, Waibel S, Guntinas-Lichius O, Lenzen M, Neiss WF, et al. 2003. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 100:4790-95
2. Austin L, Arendash GW, Gordon MN, Diamond DM, DiCarlo G, et al. 2003. Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice. Behav. Neurosci. 117:478-84
3. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, et al. 2002. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci. 22:7873-78
4. Bade S, Frey A. 2007. Potential of active and passive immunizations for the prevention and therapy of transmissible spongiform encephalopathies. Expert Rev. Vaccin. 6:153-68
5. Bales KR, Tzavara ET, Wu S, Wade MR, Bymaster FP, et al. 2006. Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Abeta antibody. J. Clin. Invest. 116:825-32
6. Bard F, Cannon C, Barbour R, Burke RL, Games D, et al. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:916-19
7. Bard F, Barbour R, Cannon C, Carretto R, Fox M, et al. 2003. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. USA 100:2023-28
8. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, et al. 2005. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64:94-101
9. Benner EJ, Mosley RL, Destache CJ, Lewis TB, Jackson-Lewis V, et al. 2004. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 101:9435-40
10. Braak H, Braak E. 1997. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18:351-57
11. Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, et al. 2005. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J. Clin. Invest. 115:428-33
12. Brody DL, Mac Donald CL, Fujimoto S, Conte V, Parsadanian M, et al. 2005. Anti-Abeta antibody treatment attenuates cognitive impairment in a mouse model of experimental traumatic brain injury. Presented at Annu. Natl. Neurotrauma Soc. Symp., 23rd, Washington DC
13. Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, et al. 2005. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J. Neurosci. 25:9096-101
14. Chen G, Chen KS, Kobayashi D, Barbour R, Motter R, et al. 2007. Active beta-amyloid immu-nization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. J. Neurosci. 27:2654-62
15. Chishti MA, Yang DS, Janus C, Phinney AL, Home P, et al. 2001. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276:21562-70
16. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, et al. 2005. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8:79-84
17. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, et al. 2003. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J. Neurosci. 23:8532-38
18. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. 2001. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging 22:721-27
19. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, et al. 2003. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9:907-13
20. Deane R, Sagare A, Hamm K, Parisi M, LaRue B, et al. 2005. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J. Neurosci. 25:11495-503
21. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, et al. 2001. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98:8850-55
22. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, et al. 2002. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5:452-57
23. Dodel R, Hampel H, Depboylu C, Lin S, Gao F, et al. 2002. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann. Neurol. 52:253-56
24. Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, et al. 2004. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75:1472-74
25. Eng JA, Frosch MP, Choi K, Rebeck GW, Greenberg SM. 2004. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann. Neurol. 55:250-56
26. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, et al. 2006. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 59:512-19
27. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, et al. 2007. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64:343-49
28. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. 2004. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14:11-20
29. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, et al. 2005. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64:1563-72
30. Frenkel D, Maron R, Burt DS, Weiner HL. 2005. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest. 115:2423-33
31. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, et al. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523-27
32. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al. 2005. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553-62
33. Goni F, Knudsen E, Schreiber F, Scholtzova H, Pankiewicz J, et al. 2005. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 133:413-21
34. Haenggeli C, Julien JP, Lee Mosley R, Perez N, Dhar A, et al. 2007. Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS. Neurobiol. Dis. 26:146-52
35. Handisurya A, Gilch S, Winter D, Shafti-Keramat S, Maurer D, et al. 2007. Vaccination with prion peptide-displaying papillomavirus-like particles induces autoantibodies to normal prion protein that interfere with pathologic prion protein production in infected cells. FEBS J. 274:1747-58
36. Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, et al. 2005. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J. Neurosci. 25:6213-20
37. Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, et al. 2006. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry 45:15157-67
38. Heppner FL, Musahl C, Arrighi I, Klein MA, Rulicke T, et al. 2001. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294:178-82
39. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, et al. 2003. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38:547-54
40. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, et al. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102
41. Hutchinson L, DeVita VT Jr. 2005. Herceptin: HERalding a new era in breast cancer care but at what cost? Nat. Clin. Pract. Oncol. 2:595
42. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, et al. 2000. Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979-82
43. Jellinger KA. 2004. Head injury and dementia. Curr. Opin. Neurol. 17:719-23
44. Jenner E. 1798. An inquiry into the causes and effects of the Variolae-Vacciniae, a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of cow pox. http://www.bartleby.eom/38/4/1.html
45. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, et al. 1997. Amyloid precursor protein processing and Abeta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA 94:1550-55
46. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al. 2004. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55:306-19
47. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, et al. 2007. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci. 27:6174-84
48. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, et al. 2005. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11:556-61
49. Knappik A, Ge L, Honegger A, Pack P, Fischer M, et al. 2000. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296:57-86
50. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, et al. 2002. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22:6331-35
51. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, et al. 2006. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J. Biol. Chem. 281:4292-99
52. Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, et al. 2005. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann. Neurol. 58:430-35
53. Lee VM, Trojanowski JQ. 2006. Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. J. Alzheimers Dis. 9:257-62
54. Legleiter J, Czilli DL, Gitter B, DeMattos RB, Holtzman DM, et al. 2004. Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J. Mol. Biol. 335:997-1006
55. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, et al. 2006. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352-57
56. Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, et al. 2003. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci. 23:10879-83
57. Masliah E, Hansen L, Adame A, Crews L, Bard F, et al. 2005a. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64:129-31
58. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, et al. 2001. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56:127-29
59. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, et al. 2005b. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46:857-68
60. Mohajeri MH, Saini K, Schultz JG, Wollmer MA, Hock C, et al. 2002. Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J. Biol. Chem. 277:33012-17
61. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, et al. 2000. Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-85
62. Morris R. 1984. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11:47-60
63. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, et al. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9:448-52
64. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. 2004. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43:321-32
65. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, et al. 2006a. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J. Biol. Chem. 281:1599-604
66. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, et al. 2006b. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 281:39413-23
67. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, et al. 2003. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46-54
68. Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickie GD, et al. 2006. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am. J. Pathol. 169:1048-63
69. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, et al. 2002. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298:1379
70. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, et al. 2001. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 58:1395-402
71. Price JL, Morris JC. 1999. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Am. Neurol. 45:358-68
72. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, et al. 2005. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 25:629-36
73. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, et al. 2005. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433:73-77
74. Scheff SW, Price DA. 2003. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol. Aging 24:1029-46
75. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-77
76. Skovronsky DM, Lee VM, Trojanowski JQ. 2006. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol. Mech. Dis. 1:151-70
77. Smith DH, Nakamura M, McIntosh TK, Wang J, Rodriguez A, et al. 1998. Brain trauma induces massive hippocampal neuron death linked to a surge in beta-amyloid levels in mice overexpressing mutant amyloid precursor protein. Am. J. Pathol. 153:1005-10
78. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. 1997. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA 94:4109-12
79. Solomon B, Koppel R, Hanan E, Katzav T. 1996. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc. Natl. Acad. Sci. USA 93:452-55
80. Tamura Y, Hamajima K, Matsui K, Yanoma S, Narita M, et al. 2005. The F(ab)′2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain. Neurobiol. Dis. 20:541-49
81. Towfighi A, Greenberg SM, Rosand J. 2005. Treatment and prevention of primary intracerebral hemorrhage. Semin. Neurol. 25:445-52
82. Urushitani M, Ezzi SA, Julien JP. 2007. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 104:2495-500
83. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al. 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-39
84. Walsh DM, Selkoe DJ. 2004. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44:181-93
85. White AR, Enever P, Tayebi M, Mushens R, Linehan J, et al. 2003. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422:80-83
86. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, et al. 2003. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 23:3745-51
87. Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, et al. 2004a. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol. Dis. 15:11-20
88. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, et al. 2004b. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflamm. 1:24